Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs

NCT02757326 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT02757326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02757326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
December 13, 2016
Completion date
May 31, 2019
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma